World Pharma News


ShireShire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

Shire RSS Channel

Display # 
Title Published Date
Shire acquires Meritage Pharma 24 February 2015
Shire acquires Premacure AB 12 March 2013
Shire and Boston Children's Hospital enter into broad research collaboration 20 November 2012
Shire continued strong product sales performance in Q3 28 October 2011
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc. 18 May 2011
Shire delivers a strong first quarter performance 28 April 2011
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® 10 January 2011
Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma 10 September 2010
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships 01 September 2010
Shire Proposes to Expand Specialist Gastrointestinal Portfolio 04 August 2010
Shire Purchases Strategic Site in Massachusetts 01 July 2010
VYVANSE® - new ADHD treatment option - now available in Canada 02 February 2010
FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity 26 October 2009
Shire Limited has changed its name to Shire plc 01 October 2008
Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million 04 July 2008
Shire plc accelerating new product sales drive revenue growth of 36% 21 February 2008
Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome 05 October 2007

© World Pharma News 2006 - 2015

Top Desktop version